The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A study of methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of response to chemotherapy and prognosis in men with castration-resistant prostate cancer (CRPC).
L. Horvath
No relevant relationships to disclose
K. L. Mahon
No relevant relationships to disclose
W. Qu
No relevant relationships to disclose
J. Devaney
No relevant relationships to disclose
M. D. Chatfield
No relevant relationships to disclose
C. Paul
No relevant relationships to disclose
R. Wykes
No relevant relationships to disclose
M. J. Boyer
No relevant relationships to disclose
M. R. Stockler
No relevant relationships to disclose
G. M. Marx
No relevant relationships to disclose
R. L. Sutherland
No relevant relationships to disclose
S. J. Clark
Consultant or Advisory Role - Epigenomics (U)
Stock Ownership - Epigenomics
Research Funding - Epigenomics